AKAP1 and cardiac hypertrophy: Taken together, these results suggest that in vivo genetic ablation of D-AKAP1 promotes pathological cardiac hypertrophy and HF, indicating D-AKAP1 as a novel repressor of pathological left ventricular remodeling and failure.